Fifty years of modern biotech, and an appetite for change

This year marks roughly fifty years since the modern biotechnology era began — an era defined by recombinant DNA, monoclonal ...
JD Supra

Compliance Considerations for GDPR Consent in Biotech Clinical Research - How One EU Framework Can Lead to Divergent Data Strategies

Biotech and digital health teams working in Europe sometimes find that the hardest General Data Protection Regulation (GDPR)[1] question in clinical research is not whether the law applies (it does), ...
Fierce Biotech

As China biotech crackdown calls reverberate in Washington, the pushback gets louder, too

The structural advantages that allow China to conduct clinical trials more quickly and at lower costs should be leveraged to ...
Forbes

How China Became the Biotech Industry’s Back-Office

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Research Scientist in Lab For years, public debate around U.S. dependence on China has ...
Nasdaq

NKGen Biotech Activates New Clinical Trial Sites in Canada and Florida for Alzheimer’s Disease Treatment Study

NKGen Biotech activates two new clinical trial sites for Alzheimer's treatment, enhancing patient access and recruitment for troculeucel therapy. NKGen Biotech, Inc. has announced the activation of ...
FierceBiotech

Medrio CEO on building stability and innovation in clinical trials

In an era of constant disruption in the healthcare industry, Medrio is doubling down on a mission of stability, efficiency and long-term impact. In a new interview with Fierce Biotech’s Chris Hayden, ...
The National Law Review

Biotech Valuations Rise as New Clinical Platforms Show Progress

AUSTIN, Texas, Nov. 24, 2025 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: As advanced biotech programs move closer to commercialization, fair-value adjustments under U.S. Generally Accepted ...
Morningstar

Kelun-Biotech Announces Three Clinical Study Results Selected for Oral Presentations at 2026 ASCO Annual Meeting

Session Date and Time: May 29, 3:12 PM-3:24 PM CDT | Lung Cancer-Non-Small Cell Metastatic Title: Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from ...
NC Biotech

New partnership aims to improve access to rare disease trials, includes NC clinical research site

For patients with rare diseases, finding a relevant clinical trial can be a difficult and fragmented process, but a new ...

Kelun-Biotech: Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that the results of the Phase III clinical study OptiTROP-Lung05 ...